Jeremy Bastid

– PRESS RELEASE – For immediate release OREGA Biotech enters into an Exclusive License Agreement with Genmab for a novel immuno-oncology antibody program   OREGA Biotech grants Genmab rights to its first-in-class antibody against a novel, undisclosed immuno-oncology target Under the License Agreement with OREGA Biotech, Genmab will obtain the exclusive, worldwide right to develop and commercialize novel antibody therapeutics utilizing OREGA Biotech’s first-in-class antibody OREGA Biotech to receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments along with royalties on commercial sales.   Lyon, France, december 6th, 2022 – OREGA Biotech announces today an exclusive license agreement under which OREGA Biotech grants Genmab full, worldwide rights to its first-in-class immuno-oncology antibody program against a novel and undisclosed target. This license agreement results from a fruitful research collaboration between the two companies initiated in 2020. “We are thrilled to partner with Genmab, the renowned international biotechnology company“, said Jeremy Bastid, Chief Executive Officer of OREGA Biotech. “Our team discovered the role of this novel target in impairing the response to the PD1/PDL1 immune checkpoint inhibitors and demonstrated that a neutralizing antibody could reverse this effect and improve the response to cancer immunotherapy. We have been working very closely with Genmab’s scientific team for more than 2 years and we are convinced that their scientific skills and development capabilities will be of paramount importance to further develop this asset”, he added. Gilles Alberici, President of OREGA Biotech, further commented: “This licensing agreement marks another major step forward for our company and team after the successful out-licensing of our CD39 antibody program which is now entering phase 2 clinical trial. Given the track record of Genmab in developing and delivering innovations to the patients, we believe that Genmab is very well positioned to bring this novel antibody program to the clinic”, he added. Genmab will be responsible for the research, development, manufacturing and commercialization of the antibody. The parties will aim to enter into an additional agreement for OREGA Biotech to support Genmab’s preclinical research activities related to this antibody. “I would like to take the opportunity of this announcement to congratulate our scientists who did a fantastic work in advancing this antibody program and collaborating successfully with our Genmab’s colleagues despite the Covid-19 pandemic. I also would like to thank our partners from Inserm Transfert for their continued support during the licensing process”, Jeremy Bastid […]

Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming 37th SITC annual meeting to be held November 8-12 2022 (Boston, MA & virtual).

– PRESS RELEASE – For immediate release Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer   Lyon, France, June 6th, 2022 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech commenced the CD39 program at its inception in 2010, then entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). Jeremy Bastid, Chief Executive Officer of OREGA Biotech, commented “We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company. Our academic cofounders are also very proud of having been involved in the discovery of the immunoregulatory role of the adenosine pathway in cancer, the components of which are now being targeted in multiple clinical trials”. Download the Press Release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 jeremy.bastid@orega-biotech.com   For more information: www.orega-biotech.com

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana.